News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer – UroToday.com
UroToday.com
Dec 16, 2024, 19:31

RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer – UroToday.com

UroToday.com shared a post on X:

“RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer.

Giulia Marvaso shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT and short-course hormonal therapy in oligorecurrent PCa.

Results show enhanced biochemical and clinical progression-free survival with the combination, though select patients may still benefit from SBRT alone. Future analyses will explore QoL and molecular data to refine patient selection.”

RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer - UroToday.com

Proceed to the video attached to the post.

More posts featuring UroToday.com.

cancer Giulia Marvaso OncoDaily Oncology RADIOSA UroToday.com Zachary Klaassen
Special Coverage
Insight
Dec 16, 2024, 19:31
RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer - UroToday.com
Insight
Dec 16, 2024, 19:28
Akhil Santhosh: The key differences between “KEYNOTE 522” and “CAMRELIEF”
Blog
Dec 16, 2024, 19:16
Ameish Govindarajan joins Cleveland Clinic MD for Hematology Oncology Fellowship
Blog
Dec 16, 2024, 19:13
Suresh S. Ramalingam on insurance coverage challenges for Keytruda in NSCLC Patients
Insight
Dec 16, 2024, 19:10
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response
Insight
Dec 16, 2024, 19:07
Julie Hallet: Guidance on biomarkers gene therapy for NETs
Blog
Dec 16, 2024, 19:04
Elshad Hasanov: Vision for the future - a colorful, beautiful, and healthy brain - free of metastasis
Blog
Dec 16, 2024, 19:00
Xiuning Le: Successful EGFR Resisters Research Summit
Insight
Dec 16, 2024, 18:57
Next generation sequencing-based MSI scoring predict benefit in dMMR tumors treated with nivolumab
Blog
Dec 16, 2024, 18:53
City Cancer Challenge - A career-defining challenge proving that nothing is impossible
Blog
Dec 16, 2024, 18:48
Ben Neel on resistance and identification of synthetic lethal targets in KRAS STK11 mutant NSCLC
Blog
Dec 16, 2024, 18:45
Douglas Flora: Working alongside some of the brightest minds in healthcare